Accordingly, reducing SLN expression in a mouse model of DMD (dystrophin/utrophin double mutant) results in enhanced SERCA function and mitigation of skeletal muscle and cardiac pathology (suggesting that reducing SLN levels is promising for treating DMD [128]). This evidence concerns the gene DMD and Duchenne muscular dystrophy.